Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valter Gattei

Showing results (91-100 of 190) with videos related to

Pageof 19
Sort By:
Journal of Translational Medicine|February 1, 2012
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemiaPietro Bulian, Davide Rossi, Francesco Forconi, et al.
British Journal of Haematology|August 22, 2013
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphomaAndrea Rinaldi, Afua Adjeiwaa Mensah, Ivo Kwee, et al.
Journal of Immunological Methods|October 4, 2005
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevanceAntonella Zucchetto, Paolo Sonego, Massimo Degan, et al.
British Journal of Haematology|May 15, 2009
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factorsDavide Rossi, Elisa Sozzi, Alessia Puma, et al.
Blood|February 7, 2014
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemiaDavide Rossi, Hossein Khiabanian, Valeria Spina, et al.
Oncotarget|April 21, 2015
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21Sylvia Ganghammer, Evelyn Hutterer, Elisabeth Hinterseer, et al.
Cancer|November 15, 2005
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemiaGiovanni Del Poeta, Maria Ilaria Del Principe, Maria Antonietta Irno Consalvo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemiaPietro Bulian, Tait D Shanafelt, Chris Fegan, et al.
Oncotarget|April 19, 2017
High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemiaElena Vendramini, Marco Giordan, Emanuela Giarin, et al.
Haematologica|July 22, 2008
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemiaDavide Rossi, Antonella Zucchetto, Francesca Maria Rossi, et al.
Pageof 19

Showing results (91-100 of 190) with videos related to

Sort By:
Pageof 19
Journal of Translational Medicine|February 1, 2012
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemiaPietro Bulian, Davide Rossi, Francesco Forconi, et al.
British Journal of Haematology|August 22, 2013
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphomaAndrea Rinaldi, Afua Adjeiwaa Mensah, Ivo Kwee, et al.
Journal of Immunological Methods|October 4, 2005
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevanceAntonella Zucchetto, Paolo Sonego, Massimo Degan, et al.
British Journal of Haematology|May 15, 2009
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factorsDavide Rossi, Elisa Sozzi, Alessia Puma, et al.
Blood|February 7, 2014
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemiaDavide Rossi, Hossein Khiabanian, Valeria Spina, et al.
Oncotarget|April 21, 2015
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21Sylvia Ganghammer, Evelyn Hutterer, Elisabeth Hinterseer, et al.
Cancer|November 15, 2005
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemiaGiovanni Del Poeta, Maria Ilaria Del Principe, Maria Antonietta Irno Consalvo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemiaPietro Bulian, Tait D Shanafelt, Chris Fegan, et al.
Oncotarget|April 19, 2017
High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemiaElena Vendramini, Marco Giordan, Emanuela Giarin, et al.
Haematologica|July 22, 2008
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemiaDavide Rossi, Antonella Zucchetto, Francesca Maria Rossi, et al.
Pageof 19